Exosomes from Dendritic Cells Loaded with Chaperone-Rich Cell Lysates Elicit a Potent T Cell Immune Response Against Intracranial Glioma in Mice

Journal of Molecular Neuroscience

Volumn 56, Issue 3, 2015, Pages 631-643

  Bu, Ning ^a   Wu, Haiqin ^a   Zhang, Guilian ^a   Zhan, Shuqin ^a   Zhang, Ru ^a   Sun, Hong ^a   Du, Yun ^a   Yao, Li ^a   Wang, Huqing ^a  

^a XI'AN JIAOTONG UNIVERSITY   (China)

Author keywords

Anti tumor vaccine; Casitas B cell lineage lymphoma; Chaperone rich cell lysates; Dendritic cell derived exosomes; Dendritic cells; Glioma

Indexed keywords

CHAPERONE; GAMMA INTERFERON; INTERLEUKIN 2; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; CBL PROTEIN; HEAT SHOCK PROTEIN; PROTEIN KINASE B;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; B LYMPHOCYTE; CANCER INFILTRATION; CANCER SURVIVAL; CANCER TISSUE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL LYSATE; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; EXOSOME; FEMALE; GLIOMA; GLIOMA CELL; IMMUNE RESPONSE; IN VITRO STUDY; INTRACRANIAL GLIOMA; LYMPHOMA CELL LINE; MOUSE; NONHUMAN; T LYMPHOCYTE; ANIMAL; BRAIN NEOPLASMS; C57BL MOUSE; GENETICS; IMMUNOLOGY; IMMUNOTHERAPY; METABOLISM; SIGNAL TRANSDUCTION; TRANSPLANTATION; TUMOR CELL LINE;

MUS;

ANIMALS; BRAIN NEOPLASMS; CELL LINE, TUMOR; DENDRITIC CELLS; EXOSOMES; FEMALE; GLIOMA; HEAT-SHOCK PROTEINS; IMMUNOTHERAPY; MICE; MICE, INBRED C57BL; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-CBL; SIGNAL TRANSDUCTION; T-LYMPHOCYTES, CYTOTOXIC;

EID: 84931563361     PISSN: 08958696     EISSN: 15591166     Source Type: Journal    
DOI: 10.1007/s12031-015-0506-9     Document Type: Article

References (64)

1. Ailawadi S, Wang X, Gu H, Fan GC (2015) Pathologic function and therapeutic potential of exosomes in cardiovascular disease. Biochim Biophys Acta 1852:1–11
2. Bachmaier K, Krawczyk C, Kozieradzki I, Kong YY, Sasaki T, Oliveira-dos-Santos A, Mariathasan S, Bouchard D, Wakeham A, Itie A et al (2000) Negative regulation of lymphocyte activation and autoimmunity by the molecular adaptor Cbl-b. Nature 403:211–216
3. Basu S, Srivastava PK (1999) Calreticulin, a peptide-binding chaperone of the endoplasmic reticulum, elicits tumor- and peptide-specific immunity. J Exp Med 189:797–802
4. Bu N, Wu H, Sun B, Zhang G, Zhan S, Zhang R, Zhou L (2011) Exosome-loaded dendritic cells elicit tumor-specific CD8+ cytotoxic T cells in patients with glioma. J Neurooncol 104:659–667
5. Bu N, Wu H, Zhang G, Ma X, Zhao P, Zhai N, Xiang L, Cao H, Yang X, Liu J (2014) Exosome from chaperone-rich cell lysates-loaded dendritic cells produced by CELLine 1000 culture system exhibits potent immune activity. Biochem Biophys Res Commun 6:02159–02157
6. Buzas EI, Gyorgy B, Nagy G, Falus A, Gay S (2014) Emerging role of extracellular vesicles in inflammatory diseases. Nat Rev Rheumatol 10:356–364
7. Cantrell J, Larmonier C, Janikashvili N, Bustamante S, Fraszczak J, Herrell A, Lundeen T, LaCasse JC, Situ E, Larmonier N et al (2010) Signaling pathways induced by a tumor-derived vaccine in antigen presenting cells. Immunobiology 215:535–544
8. Caudill MM, Li Z (2001) HSPPC-96: a personalised cancer vaccine. Expert Opin Biol Ther 1:539–547
9. Chan AC, Dalton M, Johnson R, Kong GH, Wang T, Thoma R, Kurosaki T (1995) Activation of ZAP-70 kinase activity by phosphorylation of tyrosine 493 is required for lymphocyte antigen receptor function. EMBO J 14:2499–2508
10. Chen W, Wang J, Shao C, Liu S, Yu Y, Wang Q, Cao X (2006) Efficient induction of antitumor T cell immunity by exosomes derived from heat-shocked lymphoma cells. Eur J Immunol 36:1598–1607
11. Chiang YJ, Kole HK, Brown K, Naramura M, Fukuhara S, Hu RJ, Jang IK, Gutkind JS, Shevach E, Gu H (2000) Cbl-b regulates the CD28 dependence of T-cell activation. Nature 403:216–220
12. Ehtesham M, Kabos P, Kabosova A, Neuman T, Black KL, Yu JS (2002) The use of interleukin 12-secreting neural stem cells for the treatment of intracranial glioma. Cancer Res 62:5657–5663
13. Escudier B, Dorval T, Chaput N, Andre F, Caby MP, Novault S, Flament C, Leboulaire C, Borg C, Amigorena S et al (2005) Vaccination of metastatic melanoma patients with autologous dendritic cell (DC) derived-exosomes: results of the first phase I clinical trial. J Transl Med 3:10
14. Fang D, Liu YC (2001) Proteolysis-independent regulation of PI3K by Cbl-b-mediated ubiquitination in T cells. Nat Immunol 2:870–875
15. Fournel M, Davidson D, Weil R, Veillette A (1996) Association of tyrosine protein kinase Zap-70 with the protooncogene product p120c-cbl in T lymphocytes. J Exp Med 183:301–306
16. Graner M, Raymond A, Akporiaye E, Katsanis E (2000a) Tumor-derived multiple chaperone enrichment by free-solution isoelectric focusing yields potent antitumor vaccines. Cancer Immunol Immunother 49:476–484
17. Graner M, Raymond A, Romney D, He L, Whitesell L, Katsanis E (2000b) Immunoprotective activities of multiple chaperone proteins isolated from murine B-cell leukemia/lymphoma. Clin Cancer Res 6:909–915
18. Graner MW, Zeng Y, Feng H, Katsanis E (2003) Tumor-derived chaperone-rich cell lysates are effective therapeutic vaccines against a variety of cancers. Cancer Immunol Immunother 52:226–234
19. Guntinas-Lichius O (2008) Cetuximab in head and neck cancer. N Engl J Med 359:2725, author reply 2726
20. Guo J, Wang B, Zhang M, Chen T, Yu Y, Regulier E, Homann HE, Qin Z, Ju DW, Cao X (2002) Macrophage-derived chemokine gene transfer results in tumor regression in murine lung carcinoma model through efficient induction of antitumor immunity. Gene Ther 9:793–803
21. Hao S, Bai O, Yuan J, Qureshi M, Xiang J (2006) Dendritic cell-derived exosomes stimulate stronger CD8+ CTL responses and antitumor immunity than tumor cell-derived exosomes. Cell Mol Immunol 3:205–211
22. Hao S, Bai O, Li F, Yuan J, Laferte S, Xiang J (2007) Mature dendritic cells pulsed with exosomes stimulate efficient cytotoxic T-lymphocyte responses and antitumour immunity. Immunology 120:90–102
23. Janetzki S, Palla D, Rosenhauer V, Lochs H, Lewis JJ, Srivastava PK (2000) Immunization of cancer patients with autologous cancer-derived heat shock protein gp96 preparations: a pilot study. Int J Cancer 88:232–238
24. Jeon MS, Atfield A, Venuprasad K, Krawczyk C, Sarao R, Elly C, Yang C, Arya S, Bachmaier K, Su L et al (2004) Essential role of the E3 ubiquitin ligase Cbl-b in T cell anergy induction. Immunity 21:167–177
25. Larmonier N, Cantrell J, Lacasse C, Li G, Janikashvili N, Situ E, Sepassi M, Andreansky S, Katsanis E (2008) Chaperone-rich tumor cell lysate-mediated activation of antigen-presenting cells resists regulatory T cell suppression. J Leukoc Biol 83:1049–1059
26. Li G, Zeng Y, Chen X, Larmonier N, Sepassi M, Graner MW, Andreansky S, Brewer MA, Katsanis E (2007) Human ovarian tumour-derived chaperone-rich cell lysate (CRCL) elicits T cell responses in vitro. Clin Exp Immunol 148:136–145
27. Lin AE, Mak TW (2007) The role of E3 ligases in autoimmunity and the regulation of autoreactive T cells. Curr Opin Immunol 19:665–673
28. Liu YC (2004) Ubiquitin ligases and the immune response. Annu Rev Immunol 22:81–127
29. Luketic L, Delanghe J, Sobol PT, Yang P, Frotten E, Mossman KL, Gauldie J, Bramson J, Wan Y (2007) Antigen presentation by exosomes released from peptide-pulsed dendritic cells is not suppressed by the presence of active CTL. J Immunol 179:5024–5032
30. Lund-Johansen F, Olweus J (1999) Dendritic cells—strong candidates for immunotherapy. Tidsskr Nor Laegeforen 119:2510–2514
31. Mahaweni NM, Kaijen-Lambers ME, Dekkers J, Aerts JG, Hegmans JP (2013) Tumour-derived exosomes as antigen delivery carriers in dendritic cell-based immunotherapy for malignant mesothelioma. J Extracell Vesicles 24
32. Maher EA, Furnari FB, Bachoo RM, Rowitch DH, Louis DN, Cavenee WK, DePinho RA (2001) Malignant glioma: genetics and biology of a grave matter. Genes Dev 15:1311–1333
33. Mao XG, Zhang X, Zhen HN (2009) Progress on potential strategies to target brain tumor stem cells. Cell Mol Neurobiol 29:141–155
34. Mignot G, Roux S, Thery C, Segura E, Zitvogel L (2006) Prospects for exosomes in immunotherapy of cancer. J Cell Mol Med 10:376–388
35. Morse MA, Garst J, Osada T, Khan S, Hobeika A, Clay TM, Valente N, Shreeniwas R, Sutton MA, Delcayre A et al (2005) A phase I study of dexosome immunotherapy in patients with advanced non-small cell lung cancer. J Transl Med 3:9
36. Murphy MA, Schnall RG, Venter DJ, Barnett L, Bertoncello I, Thien CB, Langdon WY, Bowtell DD (1998) Tissue hyperplasia and enhanced T-cell signalling via ZAP-70 in c-Cbl-deficient mice. Mol Cell Biol 18:4872–4882
37. Nair S, Wearsch PA, Mitchell DA, Wassenberg JJ, Gilboa E, Nicchitta CV (1999) Calreticulin displays in vivo peptide-binding activity and can elicit CTL responses against bound peptides. J Immunol 162:6426–6432
38. Navabi H, Croston D, Hobot J, Clayton A, Zitvogel L, Jasani B, Bailey-Wood R, Wilson K, Tabi Z, Mason MD et al (2005) Preparation of human ovarian cancer ascites-derived exosomes for a clinical trial. Blood Cells Mol Dis 35:149–152
39. Okada H, Kalinski P, Ueda R, Hoji A, Kohanbash G, Donegan TE, Mintz AH, Engh JA, Bartlett DL, Brown CK et al (2011) Induction of CD8+ T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with {alpha}-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in patients with recurrent malignant glioma. J Clin Oncol 29:330–336
40. Parajuli P, Mathupala S, Mittal S, Sloan AE (2007) Dendritic cell-based active specific immunotherapy for malignant glioma. Expert Opin Biol Ther 7:439–448
41. Pedraza-Alva G, Merida LB, del Rio R, Fierro NA, Cruz-Munoz ME, Olivares N, Melchy E, Igras V, Hollander GA, Burakoff SJ et al (2011) CD43 regulates the threshold for T cell activation by targeting Cbl functions. IUBMB Life 63:940–948
42. Ramanathan P, Ganeshrajah S, Raghanvan RK, Singh SS, Thangarajan R (2014) Development and clinical evaluation of dendritic cell vaccines for HPV related cervical cancer—a feasibility study. Asian Pac J Cancer Prev 15:5909–5916
43. Rangachari M, Penninger JM (2004) Negative regulation of T cell receptor signals. Curr Opin Pharmacol 4:415–422
44. Rao N, Lupher ML Jr, Ota S, Reedquist KA, Druker BJ, Band H (2000) The linker phosphorylation site Tyr292 mediates the negative regulatory effect of Cbl on ZAP-70 in T cells. J Immunol 164:4616–4626
45. Raposo G, Nijman HW, Stoorvogel W, Liejendekker R, Harding CV, Melief CJ, Geuze HJ (1996) B lymphocytes secrete antigen-presenting vesicles. J Exp Med 183:1161–1172
46. Sabel MS (2009) Cryo-immunology: a review of the literature and proposed mechanisms for stimulatory versus suppressive immune responses. Cryobiology 58:1–11
47. Sanai N, Berger MS (2008) Glioma extent of resection and its impact on patient outcome. Neurosurgery 62:753–764, discussion 264-756
48. Sluijter JP, Verhage V, Deddens JC, van den Akker F, Doevendans PA (2014) Microvesicles and exosomes for intracardiac communication. Cardiovasc Res 102:302–311
49. Srivastava PK, Amato RJ (2001) Heat shock proteins: the ‘Swiss Army Knife’ vaccines against cancers and infectious agents. Vaccine 19:2590–2597
50. Steinman RM (2012) Decisions about dendritic cells: past, present, and future. Annu Rev Immunol 30:1–22
51. Stoorvogel W, Kleijmeer MJ, Geuze HJ, Raposo G (2002) The biogenesis and functions of exosomes. Traffic 3:321–330
52. Tamura Y, Peng P, Liu K, Daou M, Srivastava PK (1997) Immunotherapy of tumors with autologous tumor-derived heat shock protein preparations. Science 278:117–120
53. Thien CB, Langdon WY (2005) c-Cbl and Cbl-b ubiquitin ligases: substrate diversity and the negative regulation of signalling responses. Biochem J 391:153–166
54. Udono H, Srivastava PK (1994) Comparison of tumor-specific immunogenicities of stress-induced proteins gp96, hsp90, and hsp70. J Immunol 152:5398–5403
55. Wolfers J, Lozier A, Raposo G, Regnault A, Thery C, Masurier C, Flament C, Pouzieux S, Faure F, Tursz T et al (2001) Tumor-derived exosomes are a source of shared tumor rejection antigens for CTL cross-priming. Nat Med 7:297–303
56. Yang C, Robbins PD (2011) The roles of tumor-derived exosomes in cancer pathogenesis. Clin Dev Immunol 2011:842849
57. Yingchun L, Xiujuan Q, Jinglei Q, Ye Z, Jing L, Yuee T, Xuejun H, Kezuo H, Yunpeng L (2011) E3 ubiquitin ligase Cbl-b potentiates the apoptotic action of arsenic trioxide by inhibiting the PI3K/Akt pathway. Braz J Med Biol Res 44:105–111
58. Zeng Y, Feng H, Graner MW, Katsanis E (2003) Tumor-derived, chaperone-rich cell lysate activates dendritic cells and elicits potent antitumor immunity. Blood 101:4485–4491
59. Zeng Y, Graner MW, Feng H, Li G, Katsanis E (2004) Imatinib mesylate effectively combines with chaperone-rich cell lysate-loaded dendritic cells to treat bcr-abl+ murine leukemia. Int J Cancer 110:251–259
60. Zeng Y, Chen X, Larmonier N, Larmonier C, Li G, Sepassi M, Marron M, Andreansky S, Katsanis E (2006a) Natural killer cells play a key role in the antitumor immunity generated by chaperone-rich cell lysate vaccination. Int J Cancer 119:2624–2631
61. Zeng Y, Graner MW, Katsanis E (2006b) Chaperone-rich cell lysates, immune activation and tumor vaccination. Cancer Immunol Immunother 55:329–338
62. Zhang J, Bardos T, Li D, Gal I, Vermes C, Xu J, Mikecz K, Finnegan A, Lipkowitz S, Glant TT (2002) Cutting edge: regulation of T cell activation threshold by CD28 costimulation through targeting Cbl-b for ubiquitination. J Immunol 169:2236–2240
63. Zhao MF, Qu XJ, Qu JL, Jiang YH, Zhang Y, Hou KZ, Deng H, Liu YP (2013) The role of E3 ubiquitin ligase Cbl proteins in interleukin-2-induced Jurkat T-cell activation. Biomed Res Int 2013:430861
64. Zitvogel L, Regnault A, Lozier A, Wolfers J, Flament C, Tenza D, Ricciardi-Castagnoli P, Raposo G, Amigorena S (1998) Eradication of established murine tumors using a novel cell-free vaccine: dendritic cell-derived exosomes. Nat Med 4:594–600